A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials
Trial details
- Registry ID
- NCT06736262
- Drugs studied
- Briquilimab
TrialRedline tracks 1 clinical trial sponsored by Jasper Therapeutics, Inc.: 1 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria TrialsNCT06736262 | Briquilimab | Terminated | 2026-07-21Actual |
Names as written in the registry records.
Before: Estimated. After: Actual.
Before: 13 Aug 2026. After: 21 Jul 2026.
Before: Active not recruiting. After: Terminated.
Before: Estimated. After: Actual.
Before: 90 participants (planned). After: 67 participants (actual).
Before: 1 Dec 2026. After: 13 Aug 2026.
Before: Enrolling by invitation. After: Active not recruiting.